SCHEDULE: Oramed Discloses 4.9% Stake in Scilex Holding Co

Oramed Pharmaceuticals Inc. has disclosed a 4.9% beneficial ownership stake in Scilex Holding Co., primarily through warrants and convertible notes.

Summary

• Oramed Pharmaceuticals Inc. reported beneficial ownership of 437,510 shares of Scilex Holding Co. common stock.
• This represents 4.9% of Scilex Holding Co.'s outstanding common stock.
• The ownership is comprised of shares issuable upon the exercise of warrants and conversion of convertible notes held by Oramed, exercisable within 60 days of the filing date.
• The percentage is calculated based on 8,491,267 shares of Scilex Common Stock outstanding as of December 5, 2025, plus the 437,510 shares beneficially owned by Oramed.
• Oramed Pharmaceuticals Inc. is a Delaware corporation.
• The filing certifies that the securities were not acquired for the purpose of changing or influencing control of Scilex Holding Co.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive disclosure, confirming Oramed's continued significant, non-controlling stake in Scilex, which can be seen as a vote of confidence without implying control changes.

Positives

• Oramed Pharmaceuticals Inc. maintains a significant, albeit non-controlling, stake in Scilex Holding Co., indicating a continued investment interest.
• The ownership is derived from warrants and convertible notes, suggesting a prior strategic investment or financing arrangement.

Negatives

• The beneficial ownership percentage of 4.9% is below the 5% threshold, which might reduce Oramed's direct influence on Scilex's corporate actions compared to a 5%+ holder.

Risks

• The filing explicitly states that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Scilex Holding Co., mitigating a potential risk of hostile takeover or activist investor intervention.

Future Outlook

Not applicable, as this filing is a disclosure of current ownership, not forward-looking statements from Scilex Holding Co.

Management Comments

• To the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

Industry Context

StockSavvy.ai notes that Oramed Pharmaceuticals Inc.'s continued beneficial ownership in Scilex Holding Co. suggests a strategic interest in the pain management and neuroscience sectors, where Scilex operates. This type of investment by one pharmaceutical company in another can indicate either a collaborative relationship, a strategic partnership, or simply a financial investment in a related field.

Comparison to Industry Standards

• StockSavvy.ai observes that a 4.9% stake is a notable position for a corporate investor, often signaling a strategic alignment or a significant financial commitment, though it falls just below the 5% threshold that would trigger more stringent reporting requirements and potential activist investor scrutiny.

Related Party Transactions

• Oramed Pharmaceuticals Inc. holds 4.9% beneficial ownership in Scilex Holding Co. through warrants and convertible notes, indicating a significant financial relationship.

Stakeholder Impact

• Scilex Shareholders: Confirmation of a significant institutional investor (Oramed) holding a stake, which could be viewed positively as a sign of confidence, but without any intent to influence control.
• Oramed Shareholders: Disclosure of a substantial investment in another pharmaceutical company, providing transparency on Oramed's asset holdings.

Key Dates

Recommendation

The filing is a routine ownership disclosure (Schedule 13G Amendment) by Oramed Pharmaceuticals Inc. regarding its stake in Scilex Holding Co. It confirms Oramed's 4.9% beneficial ownership, derived from warrants and convertible notes, and explicitly states the securities were not acquired for the purpose of changing or influencing control. This is a factual update without new operational or financial performance data for Scilex. For investors, it primarily provides transparency on a significant institutional holding. Without additional context on Scilex's performance or Oramed's strategic intent beyond this disclosure, a 'hold' recommendation is appropriate, maintaining current positions while awaiting further operational or strategic news from either company.

Keywords

Scilex Holding Co, Oramed Pharmaceuticals, Common Stock, Beneficial Ownership, Schedule 13G, Warrants, Convertible Notes, Pharmaceutical, Biotechnology, SEC Filing